Dr Vladimir Andelkovic 293 Vulture Street, South Brisbane, Queensland 4101

Welcome to Dr Vladimir Andelkovic, a trusted institution located at 293 Vulture Street in South Brisbane, Australia. As a highly skilled and dedicated doctor, Dr Andelkovic is committed to providing his patients with the highest level of care throughout their journey, from diagnosis to treatment and beyond.

Dr Andelkovic is a Queensland trained medical oncologist at Icon Cancer Centre South Brisbane. He has completed specialist medical oncology training at renowned oncology centers in Brisbane and the Gold Coast, where he gained extensive experience in a multidisciplinary environment. His expertise spans a wide range of cancers, including breast cancer, melanoma, lung cancer, gastrointestinal cancers, and sarcomas.

With a special interest in treating bone and soft tissue tumors (sarcomas), Dr Andelkovic is an esteemed member of the Sarcoma Multidisciplinary Team at Princess Alexandra Hospital and The Wesley Hospital. He is actively involved in the Australia and New Zealand Sarcoma Association and serves as a principal investigator in several clinical trials, testing innovative treatments for sarcomas.

Dr Andelkovic is deeply passionate about medical education, clinical trials, and research. He holds senior lecturer positions at the University of Queensland and is a visiting clinical fellow at Queensland University of Technology. In addition to his expertise in sarcomas, he also has a keen interest in liver cancer and breast cancer. Notably, he is the only medical oncologist who regularly participates in the hepatocellular cancer multidisciplinary team at Princess Alexandra Hospital.

As part of his commitment to advancing cancer treatment, Dr Andelkovic is actively involved in various clinical trials. Some of his ongoing research includes a First-in-Human Study of Highly Selective FGFR2 Inhibitor for Intrahepatic Cholangiocarcinoma, a Phase 1 study of CK-301 for advanced cancers, a Phase 1/2a study of DB-1303 for advanced/metastatic solid tumors, and a Phase 1b/2 study of Sotorasib Monotherapy for advanced solid tumors with KRAS p.G12C Mutation.

At Dr Vladimir Andelkovic's institution, patients can expect compassionate care, personalized treatment plans, and access to cutting-edge research and clinical trials. Whether you require diagnosis, treatment, or ongoing support, Dr Andelkovic and his team are dedicated to providing the highest quality of care to help you on your journey to recovery.